Society guideline links: Cancer of the kidney and ureters

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●International Kidney Cancer Coalition (IKCC): An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma (2022)

●World Health Organization (WHO): Classification of tumours – Urinary and male genital tumours, 5th edition (2022)

•WHO: Classification of tumours of the urinary system and male genital organs – Part A: Renal, penile, and testicular tumours (2022)

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of urothelial cancer (2021)

●SITC: Consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (2019)

Canada

●Canadian Kidney Cancer Forum (CKCF): Consensus statement on adjuvant therapy for renal cell carcinoma (2023)

●Canadian Urological Association (CUA): Guideline for management of cystic renal lesions, update (2023)

●CUA: Guideline for management of small renal masses (2022)

●Clinical consensus statement on genetic risk assessment for hereditary renal cell carcinoma (2021)

●Kidney Cancer Research Network of Canada (KCRNC): Consensus update for management of advanced kidney cancer (2021)

●CUA/Genitourinary Medical Oncologists of Canada (GUMOC): Consensus statement for the management of unresectable locally advanced and metastatic urothelial carcinoma (2019)

●KCRNC: Consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma (2019)

●KCRNC: Consensus statement on the role of renal mass biopsy in the management of kidney cancer (2019)

●CUA: Guideline for followup of patients after treatment of non-metastatic renal cell carcinoma (2018)

●Cancer Care Ontario (CCO): Updated guideline for the use of targeted therapies in patients with inoperable locally advanced or metastatic renal cell cancer (2017)

●CCO: Focal tumour ablation for renal cell carcinoma (2016)

●KCRNC: Consensus statement for structured assessment and followup for patients with hereditary kidney tumour syndromes (2016)

●KCRNC: Canadian guideline on genetic screening for hereditary renal cell cancers (2013)

United States

●National Cancer Institute (NCI): Renal cell cancer treatment – Health professional version

●American Urological Association (AUA)/Society of Urologic Oncology (SUO): Guideline for the diagnosis and management of non-metastatic upper tract urothelial carcinoma (2023)

●American College of Radiology (ACR): ACR Appropriateness Criteria on staging of renal cell carcinoma (revised 2022)

●ACR: ACR Appropriateness Criteria on post-treatment follow-up and active surveillance of clinically localized renal cell cancer (revised 2021)

●AUA: Guideline on renal mass and localized renal cancer – Evaluation, management, and follow-up (2021)

●Clinical consensus statement on genetic risk assessment for hereditary renal cell carcinoma (2021)

●ACR: ACR Appropriateness Criteria on indeterminate renal mass (revised 2020)

●Society of Interventional Radiology (SIR): Position statement on the role of percutaneous ablation in renal cell carcinoma (2020)

●American Society of Clinical Oncology (ASCO): Clinical practice guideline for the management of small renal masses (2017)

Europe

●European Association of Urology (EAU): Guidelines on renal cell carcinoma, update (2023)

●EAU: Guidelines on upper urinary tract urothelial carcinoma, update (2023)

●European Society for Medical Oncology (ESMO): Clinical practice guideline on the use of immunotherapy in early stage and advanced renal cell carcinoma, update (2021)

•ESMO: Clinical practice guidelines on renal cell carcinoma (2019)

●Cardiovascular and Interventional Radiological Society of Europe (CIRSE): Guidelines on percutaneous ablation of small renal cell carcinoma (2016)

United Kingdom

●Royal College of Radiologists (RCR): Recommendations for cross-sectional imaging in cancer management, 2nd edition − Bladder cancer and urothelial tumours (2014)

●RCR: Recommendations for cross-sectional imaging in cancer management, 2nd edition − Renal and adrenal tumours (2014)

●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance for irreversible electroporation for treating renal cancer (2013)

●NICE: Interventional procedures guidance for laparoscopic cryotherapy for renal cancer (2011)

●NICE: Interventional procedures guidance on percutaneous cryotherapy for renal cancer (2011)

●NICE: Interventional procedures guidance on percutaneous radiofrequency ablation for renal cancer (2010)

Japan

●[In English] Pan-Asian adapted European Society for Medical Oncology (ESMO) clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with renal cell carcinoma (2021)

●[In Japanese] Japanese Urological Association (JUA): Guidelines for clinical practice of renal cancer (2017)

●[In English] JUA: Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary), 2014 edition (published 2015)

●[In Japanese] JUA: Guidelines for diagnosis and treatment of renal pelvis and ureter cancer (2014)